Tonix Pharmaceuticals Holding Corp

NASDAQ:TNXP   1:55:25 PM EDT
0.60
-0.02 (-2.53%)
Products

Tonix Pharmaceuticals Announces Results Of Pre-Ind Meeting With FDA For Tnx-102 Sl As A Potential Treatment For Long Covid Syndrome

Published: 08/24/2021 14:27 GMT
Tonix Pharmaceuticals Holding Corp (TNXP) - Tonix Pharmaceuticals Announces Results of Pre-ind Meeting With FDA for Tnx-102 Sl As a Potential Treatment for Long Covid Syndrome, Also Known As Post-acute Sequelae of Covid-19 (pasc).
Tonix Pharmaceuticals Holding Corp - Plans to Submit an Ind to Support a Phase 2 Clinical Trial of Tnx-102 Sl for Treatment of Long Covid.
Tonix Pharmaceuticals Holding - Received Official Minutes From Type B Pre-ind Meeting With FDA to Develop Tnx-102 Sl for Treatment of Long Covid.
Tonix Pharmaceuticals - Believes Minutes Provide Path to Agreement on Design of Tnx-102 Sl Phase 2 Study As Treatment for Subset of Long Covid Patients.